Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 109 resultados

MetaboKID: Dissecting renal metabolic reprogramming heterogeneity to target kidney fibrosis UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Chronic kidney disease (CKD) affects 10% of the population and fibrosis driven by excessive accumulation of extracellular matrix (ECM) is th...
2025-09-01 - 2027-08-31 | Financiado

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE UNIVERSITAETSKLINIKUM AACHEN participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

Rewind-MF: Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predict... UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2023-COG Fibrosis is estimated to be involved in 45% of global mortality, and currently no specific therapies for fibrosis in most organs exist. One...
2024-04-01 - 2029-03-31 | Financiado

MAD Control: Multifunctional Platform Technology for Magnetically Actuated Controlled Drug Release from Biodegrad... UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2022-STG The extremely popular engineering field of drug-eluting biodegradable scaffolds for regenerative medicine, cancer treatment and cardiovascul...
2024-01-01 - 2028-12-31 | Financiado

END-BC: Engineering and Delivering B Cells Using Biomaterials against Breast Cancer UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2023-POC Breast cancer (BC) is the most diagnosed cancer worldwide, and despite treatment availability, the disease remains challenging to treat, cau...
2024-01-01 - 2025-06-30 | Financiado

FibroTarg: Targeting kidney fibrosis by a novel myofibroblast specific small molecule inhibitor UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2023-POC Chronic kidney disease (CKD) is a progressive disease that is prevalent in 10% of the developed world and develops as a result of diabetes m...
2023-10-01 - 2025-03-31 | Financiado

PRIME: PRodrug technology for Immunotherapy-priming via patient-friendly at-home MEtronomic dosing UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2023-POC Immunotherapy holds great promise for curative cancer treatment. While immune checkpoint inhibitors can induce complete and long-term cures,...
2023-10-01 - 2025-03-31 | Financiado

MuSIC: Multi-sensory solutions for increasing human-building resilience in face of climate change UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Climate change is leading to more frequent and severe extreme climate phenomena, affecting both vulnerable subpopulations like children, the...
2022-12-01 - 2026-11-30 | Financiado

MuSIC: Multi-sensory solutions for increasing human-building resilience in face of climate change UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Climate change is leading to more frequent and severe extreme climate phenomena, affecting both vulnerable subpopulations like children, the...
2022-07-06 - 2026-11-30 | Financiado

TargetCKD: Identification of novel diagnostic, predictive and therapeutic strategies in chronic kidney disease UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2021-COG Chronic Kidney Disease (CKD) represents an important medical, social and economic burden with high morbidity and mortality. The prevalence o...
2022-07-01 - 2027-06-30 | Financiado

BeaT-IT: B Cell Engineering and Tertiary Lymphoid Structure Induction via Biomaterials for Cancer Immunothera... UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2021-STG Recent clinical evidence points to a potential new direction in immuno-oncology: utilizing B cells and B cell-associated tertiary lymphoid s...
2022-07-01 - 2027-06-30 | Financiado

SafePolyMed: Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions UNIVERSITAETSKLINIKUM AACHEN participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 Polypharmacy, multimorbidity and genetic heterogeneity can affect drug efficacy, raise the risk for adverse drug reactions (ADRs) and increa...
2022-05-23 - 2025-11-30 | Financiado

CGI-Clinics: Data driven cancer genome interpretation for personalised cancer treatment UNIVERSITAETSKLINIKUM AACHEN participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 CGI-Clinics aims at improving personalised medicine in oncology by optimizing genomic data interpretation (after sequencing and before advis...
2022-05-20 - 2027-10-31 | Financiado

DECODE-DKD: Decoding diabetic kidney disease UNIVERSITAETSKLINIKUM AACHEN tramitó un HORIZON EUROPE: ERC-2021-STG Diabetic kidney disease (DKD) is a rapidly growing worldwide health problem and represents one of the most serious threats in current medici...
2022-04-01 - 2027-03-31 | Financiado

BIOMET4D: Smart 4D biodegradable metallic shape shifting implants for dynamic tissue restoration UNIVERSITAETSKLINIKUM AACHEN participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDEROPEN-01 Reconstructive surgeries frequently require multiple, often complex, procedures at high social and economic costs. A shape-morphing implant...
2022-03-24 - 2026-06-30 | Financiado

EarlyLife: Gut epithelial dynamics and function at the nexus of early life infection and long term health UNIVERSITAETSKLINIKUM AACHEN tramitó un H2020: ERC-2020-ADG Infections of the gastrointestinal tract and their long-term consequences remain a major cause of childhood mortality and morbidity worldwid...
2021-07-08 - 2026-07-31 | Financiado

AIM.imaging.CKD: AI augmented Multiscale Image based Diagnostics of Chronic Kidney Disease UNIVERSITAETSKLINIKUM AACHEN tramitó un H2020: ERC-2020-COG Chronic kidney disease (CKD) is a major global health problem, affecting 10% of the world population and projected to be the fifth major cau...
2021-02-01 - 2026-04-30 | Financiado